Benzinga  Sep 28  Comment 
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the European Patent Office's Examining Division granted the Company's application titled...
newratings.com  Aug 24  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) said it has entered into a contract with Gulf Coast Regional Blood Center, 1400 La Concha, Houston, TX 77054 on August 21. This was after the company was recently informed by BioLife Plasma...
Benzinga  Aug 11  Comment 
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd. ("Emerge") to seek approval of Alferon N Injection® in Australia and New Zealand and to...
newratings.com  Aug 6  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) announced that as the Company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health Care, LLC for two years (through August 14 2017) for...
newratings.com  Jul 15  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) announced it has submitted an application for orphan drug designation to the European Medicines Agency for Alferon N Injection, an experimental therapeutic, to treat Middle East Respiratory...
newratings.com  May 11  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) said its European subsidiary, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen,...
TheStreet.com  Mar 10  Comment 
BOSTON (TheStreet) -- Some drug companies responded to the worsening Ebola epidemic in West Africa last fall by accelerating development of drugs and vaccines to treat or prevent the deadly virus. Hemispherx BioPharma saw Ebola as an...

You may also be interested in articles related to Hemispherx BioPharma (HEB):

Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.


http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki